×

WATCH NOW -

Life Sciences Investor Briefing Webcast

Newable

Newable EIS Scale-Up Fund 3

04 Sep 2019 / Tax enhanced research

Why Invest

Positives

  • Strategy: Exposure to a portfolio of deep technology companies in sectors in which the team has expertise.

Issues

  • Track record: With the current structure and process only in place for five years, the track record lacks depth.

The Investment Manager

Positives

  • Team: Diverse range of experience in team, with clear strategy and good support from its Investment Advisory Committee and angel network.

Issues

  • Company size: Although the investment team is small, the IAC and angel network bring more than adequate scale to operations.

Nuts & Bolts

  • Duration: The Fund is evergreen, with quarterly closings.
  • Diversification: The manager expects to provide between seven and ten investments for each closing.
  • Valuation: Usually changes at next financing or on writedown.

Specific Fees

  • Fees: Combination of direct fees and company charges. Unusually, fee rates decline over time.
  • Performance fee: Charged at 20% on aggregate returns over 110% of amount invested in companies on a portfolio basis. Charged on in-specie transfers.

Risks

  • Target returns: The target IRR of 20% or 3x capital suggests a high-risk investment strategy.
  • Companies: Supplying risk capital to early-stage technology companies at the start of commercialisation. There will be a spread of company returns as the successful ones will do very well, but those who fail may do so completely.
Download the full report

Request a meeting

If you'd like to be introduced to the team at Newable, get in touch.

Request a meeting